Figure 1

Antitumor effects of sorafenib and 5-fluorouracil (5-FU), alone or in combination, in hepatocellular carcinoma (HCC) cell lines. (A) Dose–response curves, correlating drug dose and cell viability, depict the effects of sorafenib and 5-FU on different HCC cell lines. The cell survival fraction is expressed relative to the untreated cells, set at 100. (B) Antiproliferation effects of 5-FU (4 mg/L, 48 h) and sorafenib (8 μM, 24 h), alone or in combination in different treatment sequences, in HCC cell lines. The cell numbers are represented as optical density (OD) values. (C) Inhibition rates of 5-FU (4 mg/L, 48 h) or sorafenib (8 μM, 24 h), alone or in combination in different treatment sequences, in HCC cell lines. The cell inhibition fraction is expressed relative to the untreated cells, set at 100. In this figure, values represent the mean ± standard deviation (SD), and each is the average of three independent determinations, with six replicates per experiment. S, sorafenib; F, 5-FU.